Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Practical outpatient pharmacotherapy for alcohol use disorder.

Kim Y, Hack LM, Ahn ES, Kim J.

Drugs Context. 2018 Feb 7;7:212308. doi: 10.7573/dic.212308. eCollection 2018. Review.

2.

Harms associated with taking nalmefene for substance use and impulse control disorders: A systematic review and meta-analysis of randomised controlled trials.

Johansen KGV, Tarp S, Astrup A, Lund H, Pagsberg AK, Christensen R.

PLoS One. 2017 Aug 29;12(8):e0183821. doi: 10.1371/journal.pone.0183821. eCollection 2017. Review.

3.

Compulsive Seekers: Our take. Two Clinicians' Perspective on a New Animal Model of Addiction.

Epstein DH, Kowalczyk WJ.

Neuropsychopharmacology. 2018 Mar;43(4):677-679. doi: 10.1038/npp.2017.132. Epub 2017 Jun 27. No abstract available.

PMID:
28653664
4.

Patient-centered care interventions for the management of alcohol use disorders: a systematic review of randomized controlled trials.

Barrio P, Gual A.

Patient Prefer Adherence. 2016 Sep 15;10:1823-1845. eCollection 2016. Review.

5.

Evaluation in alcohol use disorders - insights from the nalmefene experience.

Naudet F, Palpacuer C, Boussageon R, Laviolle B.

BMC Med. 2016 Aug 18;14(1):119. doi: 10.1186/s12916-016-0664-9.

6.

Distinct Effects of Nalmefene on Dopamine Uptake Rates and Kappa Opioid Receptor Activity in the Nucleus Accumbens Following Chronic Intermittent Ethanol Exposure.

Rose JH, Karkhanis AN, Steiniger-Brach B, Jones SR.

Int J Mol Sci. 2016 Jul 27;17(8). pii: E1216. doi: 10.3390/ijms17081216.

7.

Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers.

Fitzgerald N, Angus K, Elders A, de Andrade M, Raistrick D, Heather N, McCambridge J.

Addiction. 2016 Aug;111(8):1477-87. doi: 10.1111/add.13438. Epub 2016 Jun 5. Review.

8.

Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.

Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F.

PLoS Med. 2015 Dec 22;12(12):e1001924. doi: 10.1371/journal.pmed.1001924. eCollection 2015 Dec. Review.

9.

Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex with Men.

Santos GM, Coffin P, Santos D, Huffaker S, Matheson T, Euren J, DeMartini A, Rowe C, Hahn JA, Vlahov D, Vittinghoff E, Batki SL.

J Acquir Immune Defic Syndr. 2016 May 1;72(1):21-30. doi: 10.1097/QAI.0000000000000922.

10.

Advances in alcoholic liver disease: An update on alcoholic hepatitis.

Liang R, Liu A, Perumpail RB, Wong RJ, Ahmed A.

World J Gastroenterol. 2015 Nov 14;21(42):11893-903. doi: 10.3748/wjg.v21.i42.11893. Review.

11.

Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence.

García ML, Blasco-Algora S, Fernández-Rodríguez CM.

World J Gastroenterol. 2015 Jul 28;21(28):8516-26. doi: 10.3748/wjg.v21.i28.8516. Review.

12.

The opioid receptors as targets for drug abuse medication.

Noble F, Lenoir M, Marie N.

Br J Pharmacol. 2015 Aug;172(16):3964-79. doi: 10.1111/bph.13190. Epub 2015 Jun 26. Review.

13.

The pharmacogenetics of alcohol use disorder.

Jones JD, Comer SD, Kranzler HR.

Alcohol Clin Exp Res. 2015 Mar;39(3):391-402. doi: 10.1111/acer.12643. Epub 2015 Feb 19. Review.

14.

Nalmefene: a new approach to the treatment of alcohol dependence.

Paille F, Martini H.

Subst Abuse Rehabil. 2014 Aug 8;5:87-94. doi: 10.2147/SAR.S45666. eCollection 2014. Review. Erratum in: Subst Abuse Rehabil. 2015;6:81.

15.

Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment.

Wackernah RC, Minnick MJ, Clapp P.

Subst Abuse Rehabil. 2014 Jan 23;5:1-12. doi: 10.2147/SAR.S37907. eCollection 2014. Review.

16.

Targeted opioid receptor antagonists in the treatment of alcohol use disorders.

Niciu MJ, Arias AJ.

CNS Drugs. 2013 Oct;27(10):777-87. doi: 10.1007/s40263-013-0096-4. Review.

17.
18.

Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent.

Al-Eitan LN, Jaradat SA, Su SY, Tay GK, Hulse GK.

Pharmgenomics Pers Med. 2012;5:99-111. doi: 10.2147/PGPM.S33351. Epub 2012 Sep 7.

19.

Future pharmacological treatments for substance use disorders.

Forray A, Sofuoglu M.

Br J Clin Pharmacol. 2014 Feb;77(2):382-400. doi: 10.1111/j.1365-2125.2012.04474.x. Review.

20.

A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men.

Morgenstern J, Kuerbis AN, Chen AC, Kahler CW, Bux DA Jr, Kranzler HR.

J Consult Clin Psychol. 2012 Oct;80(5):863-75. Epub 2012 May 21.

Supplemental Content

Support Center